Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 7, 2015, Pages 774-787

  Dentali, Francesco ^a,e   Sironi, Anna Paola ^a   Gianni, Monica ^b   Orlandini, Francesco ^c   Guasti, Luigina ^a   Grandi, Anna Maria ^a   Franchini, Massimo ^d   Ageno, Walter ^a   Squizzato, Alessandro ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b Tradate Hospital   (Italy)

^c Ligurian East Hospital   (Italy)

^d CARLO POMA HOSPITAL   (Italy)

^e OSPEDALE DI CIRCOLO   (Italy)

Author keywords

atrial fibrillation; direct oral anticoagulants; gender; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; NON VITAMIN K ANTAGONIST ORAL ANTICOAGULANT; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ATRIAL FIBRILLATION; BLEEDING; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; FEMALE; HUMAN; MALE; META ANALYSIS; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; SEX DIFFERENCE; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEXUAL DEVELOPMENT;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX CHARACTERISTICS; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84943616531     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1564042     Document Type: Conference Paper

References (29)

1. Reeves M. J., Bushnell C. D., Howard G., et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol: 2008; 7 10 915 926
2. McRae S., Tran H., Schulman S., Ginsberg J., Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet: 2006; 368 9533 371 378
3. Berger J. S., Roncaglioni M. C., Avanzini F., Pangrazzi I., Tognoni G., Brown D. L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA: 2006; 295 3 306 313
4. Lapner S., Cohen N., Kearon C. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. J Thromb Haemost: 2014; 12 5 595 605
5. Seeland U., Regitz-Zagrosek V. Sex and gender differences in cardiovascular drug therapy. Handbook Exp Pharmacol: 2012; 214 211 236
6. Schulman S. Advantages and limitations of the new anticoagulants. J Intern Med: 2014; 275 1 1 11
7. Ruff C. T., Giugliano R. P., Braunwald E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet: 2014; 383 9921 955 962
8. van der Hulle T., Kooiman J., den Exter P. L., Dekkers O. M., Klok F. A., Huisman M. V. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost: 2014; 12 3 320 328
9. Moher D., Liberati A., Tetzlaff J., Altman D. G.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med: 2009; 151 4 264 269, W64
10. Schulman S., Kearon C.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost: 2005; 3 4 692 694
11. Jadad A. R., Moore R. A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials: 1996; 17 1 1 12
12. Connolly S. J., Ezekowitz M. D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
13. Patel M. R., Mahaffey K. W., Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
14. Granger C. B., Alexander J. H., McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
15. Giugliano R. P., Ruff C. T., Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
16. Agnelli G., Buller H. R., Cohen A., et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med: 2013; 369 9 799 808
17. Bauersachs R., Berkowitz S. D., Brenner B., et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
18. Büller H. R., Prins M. H., Lensin A. W., et al. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med: 2012; 366 14 1287 1297
19. Schulman S., Kearon C., Kakkar A. K., et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med: 2009; 361 24 2342 2352
20. Schulman S., Kakkar A. K., Goldhaber S. Z., et al. RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation: 2014; 129 7 764 772
21. Büller H. R., Décousus H., Grosso M. A., et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med: 2013; 369 15 1406 1415
22. Agnelli G., Buller H. R., Cohen A., et al. PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med: 2013; 368 8 699 708
23. Schulman S., Kearon C., Kakkar A. K., et al. RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med: 2013; 368 8 709 718
24. Hylek E. M., Held C., Alexander J. H., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol: 2014; 63 20 2141 2147
25. Pancholy S. B., Sharma P. S., Pancholy D. S., Patel T. M., Callans D. J., Marchlinski F. E. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol: 2014; 113 3 485 490
26. Harris D. J., Douglas P. S. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med: 2000; 343 7 475 480
27. Murthy V. H., Krumholz H. M., Gross C. P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA: 2004; 291 22 2720 2726
28. Bushnell C., McCullough L. D., Awad I. A., et al. American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council for High Blood Pressure Research. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke: 2014; 45 5 1545 1588
29. Feinberg W. M., Blackshear J. L., Laupacis A., Kronmal R., Hart R. G. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med: 1995; 155 5 469 473